EnglishFrançais

Ce site a été mis à jour le 14 mars 2017

Osteoporosis and Breast cancer - No. 693 Imprimer
Two studies published today in Nature show how progestin, can cause breast cancer in mice by activating the protein RANKL. The studies highlight a potential role for RANKL inhibition in the management of proliferative breast disease.

Daniel Schramek et al (Nature 468, 98-102, 4 November 2010) observed that the in vivo administration of MPA triggers massive induction of the key osteoclast differentiation factor RANKL (receptor activator of NF-?B
ligand) in mammary-gland epithelial cells. Genetic inactivation of the RANKL receptor RANK in mammary-gland epithelial cells prevents MPA-induced epithelial proliferation, impairs expansion of the CD49fhi stem-cell-enriched population, and sensitizes these cells to DNA-damage-induced cell death. Deletion of RANK from the mammary epithelium results in a markedly decreased incidence and delayed onset of MPA-driven mammary cancer. These data show that the RANKL/RANK system controls the incidence and onset of progestin-driven breast cancer.

Eva Gonzalez-Suarez (Nature 468, 103-107 (4 November 2010) |
doi:10.1038/nature09495) showed that RANK and RANKL are expressed within normal, pre-malignant and neoplastic mammary epithelium, and using complementary gain-of-function (mouse mammary tumour virus (MMTV)-RANK transgenic mice) and loss-of function (pharmacological inhibition of RANKL) approaches, define a direct contribution of this pathway in mammary tumorigenesis. Accelerated pre-neoplasias and increased mammary tumour formation were observed in MMTV-RANK transgenic mice after multiparity or treatment with carcinogen and hormone (progesterone). Reciprocally, selective pharmacological inhibition of RANKL attenuated mammary tumour development not only in hormone- and carcinogen-treated MMTV-RANK and wild-type mice, but also in the MMTV-neu transgenic spontaneous tumour model. The reduction in tumorigenesis upon RANKL inhibition was preceded by a reduction in pre-neoplasias as well as rapid and sustained reductions in
hormone- and carcinogen-induced mammary epithelial proliferation and cyclin
D1 levels. Collectively, these results indicate that RANKL inhibition is acting directly on hormone-induced mammary epithelium at early stages in tumorigenesis, and the permissive contribution of progesterone to increased mammary cancer incidence is due to RANKL-dependent proliferative changes in the mammary epithelium.

 
Сделайте правильный выбор! Онлайн или реальные слоты? Играйте на реальные деньги!
займ онлайн